www.leinco.com



excellence in early discovery research™

Anti-Mouse/Human CD273 (PD-L2) (Clone 3.2.B8) Purified in vivo GOLD[™] Functional Grade kDa 1 2

Monoclonal Antibody

		250- 150- 100-	Lane 1: 2 ug reduced recombinant human PD-L2 (CD273)
Product Information		75-	Lane 2: 1 ug reduced
Product No.:	P379	50-	PD-L2 (CD273)
Clone: RRID: Isotype: Storage:	3.2.B8 AB_2737559 Mouse IgG1 Sterile 2-8°C	37-	Primary: anti-human PD-L2 (CD273) antibody
		25-	(3.2) at 10 ug/ml (Prod. No. P379)
		20- 15-	Secondary: HRP labeled goat anti-mouse at 1:1000 dilution (Prod. No. M1087)
		2825	Displicited band alter

redicted band size: ~50-70 kDa

Specificity:

Clone 3.2.B8 recognizes an epitope on mouse/human PD-L2 and has been shown to bind to both mouse and human PD-L2 equally well

Antigen Distribution:

Product Description

PD-L2 is expressed on dendritic cells, liver, few transformed cell lines, and a subset of macrophages.

Background:

PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction. Known Reactivity Species:

Human. Mouse

Format:

in vivo GOLD™, Purified in vivo Functional Grade

Immunogen:

Made in PD-L2 knockout mouse fusion partner X63-Ag8.653 myeloma cells

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Puritv

≥95% monomer by analytical SEC, >95% by SDS Page

Endotoxin

< 1.0 EU/mg as determined by the LAL method

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Product Datasheet

www.leinco.com

Storage and Stability



excellence in early discovery research™

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at \leq -70°C. Avoid Repeated Freeze Thaw Cycles.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using *in vitro* cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Applications

Applications and Recommended Usage (Quality Tested By Leinco):

Western Blot: For Western blotting, the suggested use of this reagent is 10 µg per ml (See Data Results) Country of Origin

USA

References

1.) Akbari O, Stock P, Singh AK, Lombardi V, Lee WL, Freeman GJ, Sharpe AH, Umetsu DT, Dekruyff RH. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell- dependent airway hyperreactivity in opposing directions. Mucosal Immunol. 2010; 3:81- 91. PMCID: PMC2845714

2.) Xiao Y, Yu S, Zhu B, Bedoret D, Bu X, Francisco LM, Hua P, Duke-Cohan JS, Umetsu DT, Sharpe AH, DeKruyff RH*, Freeman GJ* (* indicates co-senior authors). RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med. 2014; 211:943-59. PMCID: PMC4010901.